Pneumococcal 7-valent conjugate vaccine

Prevnar Pneumococcal 7-valent conjugate vaccine Lederle laboratories Immunization to prevent invasive pneumococcal disease... 

Measles, Mumps, Rubella, Varicella Virus Vaccine, Live [MMRV] (Proquad) Meningococcal Conjugate Vaccine (Menactra) Meningococcal Polysaccharide Vaccine (Menomune A/C/YAV-135) Pneumococcal 7-Valent Conjugate Vaccine (Prevnar)... 

Pneumococcal 7-Valent Conjugate Vaccine (Prevnar) [Vaccine]... 

Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein)... 

Prevenar [TR former used prior to approval] Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein) [FDA] PncCRM [SY]... 

There are two pneumococcal vaccines, a 7-valent conjugated vaccine for children younger than 6 years of age and a 23-purified-capsular polysaccharide antigen vaccine for adults. The 23 capsular types in the vaccine represent at least 85% to 90% of the serotypes that cause invasive pneumococcal infections among children and adults in the United States.41 After vaccination, an antigen-specific antibody response, indicated by a twofold or greater rise in serotype-specific antibody, develops within 2 to 3 weeks in 80% or more of healthy young adults.42... 

Pneumococcal Disease In October 2002, the FDA approved the use of Prevnar for immunization of infants and toddlers against otitis media— middle ear infection. Prevnar is a pneumococcal seven-valent conjugate vaccine. It is formulated with a sterile solution of saccharides conjugated to the antigen, Streptococcus pneumoniae. 

Prevnar 13 Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM 197 Protein)... 

Because patient with SCD have impaired splenic function, they are less adequately protected against encapsulated organisms such as S. pneumoniae, Hemophilus influenzae, and Salmonella. The use of pneumococcal vaccine in SCD patients has decreased the rates of morbidity and mortality dramatically. However, there are still groups of SCD children who continue to have high rates of invasive pneumococcal infections.17 Two pneumococcal vaccines are available. The 7-valent conjugate... 

PCV 7, 7-valent pneumococcal conjugated vaccine PPV 23, 23-valent pneumococcal polysaccharide vaccine. From Advisory Committee on Immunization Practices,18 Committee on Infectious Diseases,16 and Sickle Cell Disease Care Consortium.27... 

Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998-2003. Morbidity and Mortality Weekly Report (MMWR) 2005 54(36) 893-897. 

Herd immunity refers to high levels of immunization in one population resulting in protection of another unvaccinated population. For example, concentrated vaccination of children with the 7-valent pneumococcal conjugate vaccine resulted in decreased invasive Streptococcus pneumoniae infection not only in the vaccinated children, but also in elderly persons within the same community. 

The immunogenicity of 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine in 11 children has been compared with the immunogenicity of 23-valent vaccine alone in 12 children up to 2 years of age with sickle cell disease (9). IgG pneumococcal antibody concentrations were higher with combined administration, with no increase in adverse effects after immunization with 23-valent vaccine. 

Vernacchio L, Neufeld EJ, MacDonald K, Kurth S, Murakami S, Hohne C, King M, Molrine D. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998 133(2) 275-8. 

The development of tetravalent meningococcal and 13-valent pneumococcal conjugate vaccine pointed to the future need of new carrier proteins. Experimentally or in very early clinical development are several proteins. Examples are Bortedella pertussis fimbriae [109], recombinant 64 KDa Nm OMP [110], Nmporin [111], and Sp pneumolysin [112]. 

PCV 7, 7-valent pneumococcal conjugated vaccine PPV 23, 23-valent pneumococcal polysaccharide vaccine. 

Two different pneumococcal vaccines are available. The 7-valent pneumococcal conjugate vaccine (PCV 7 Prevnar) induces good antibody responses in infants. Immunization with the PCV 7 is recommended for all children less than 24 months of age. Infants should receive the first dose between 6 weeks and 6 months. Two additional doses should be given at approximately 2-month intervals, followed by a fourth dose at age 12 to 15 months. The 23-valent pneumococcal polysaccharide vaccine (PPV 23 Pneumovax 23) was not recommended for use in children less than 2 years of age because... 

Table 8 Mouse IgG and IgM Antibody Response (OD Unit of ELISA) of Four Types of Pneumococcal Conjugates Present in X-ray Irradiated 7-Valent Pneumococcal Conjugate Vaccine Lot A (Liquid) and of Corresponding Nonirradiated Controls of the Same Polysaccharide Type in Lot A... 

The era of more complex multivalent glycoconjugate vaccines having several CPS conjugated to a single protein carrier was inaugurated with the introduction of the 7-valent pneumococcal conjugate vaccine in 2000 in the USA. The vaccine led to a decrease in invasive pneumococcal disease by 75% in children younger than 5 years and by 94% for the pneumococcal serotypes contained in the vaccine. A tetravalent... 

Huang L-M, Lin T-Y, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine 2012 30(12) 2054-9. 

Frenck RW, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012 19(8) 1296-303. 

Appropriate immunizations should be a primary consideration in the prevention of infections in HSCT recipients. Immunizations against common bacterial and viral pathogens are timed to avoid periods of severe immunosuppression following HSCT when the protective response to vaccination potentially would be decreased. Current recommendations for immunization of HSCT patients include three doses each of diphtheria-pertussis-tetanus or diphtheria-tetanus, inactivated polio, conjugated H. influenzae type b, and hepatitis B vaccines at 12, 14, and 24 months after transplantation. The 23-valent pneumococcal vaccine should be administered at 12 and 24 months after HSCT, and the influenza vaccine should be administered prior to HSCT, resumed at least 6 months after transplantation, and con-... 

---